Company · CIK 0000875045 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
BIOGEN INC. · BIIB
Insider activity reported against this company. All insider holders · Files at: BIVV. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2015 SForm 4 → | Mar 26, 4:31 pm EDT | John CoxEVP Pharmaceutical Oper & Tech | 12,010 | $449.06 | $5,393,211 | 25,567 | −32.0% | plan? |
| Mar 25, 2015 MForm 4 → | Mar 26, 4:31 pm EDT | John CoxEVP Pharmaceutical Oper & Tech | 5,066 | $65.85 | $333,571 | 37,577 | — | plan? |
| Mar 20, 2015 SForm 4 → | Mar 23, 4:33 pm EDT | Eric K RowinskyDirector | 11,667 | $475.00 | $5,541,825 | 11,310 | −50.8% | plan? |
| Mar 20, 2015 MForm 4 → | Mar 23, 4:33 pm EDT | Eric K RowinskyDirector | 11,667 | $59.82 | $697,920 | 22,977 | — | plan? |
| Mar 19, 2015 SForm 4 → | Mar 20, 5:03 pm EDT | Eric K RowinskyDirector | 2,333 | $436.14 | $1,017,508 | 11,310 | −17.1% | plan? |
| Mar 19, 2015 MForm 4 → | Mar 20, 5:03 pm EDT | Eric K RowinskyDirector | 2,333 | $59.82 | $139,560 | 13,643 | — | plan? |
| Mar 17, 2015 SForm 4 → | Mar 18, 5:03 pm EDT | Eric K RowinskyDirector | 4,667 | $425.45 | $1,985,589 | 11,310 | −29.2% | plan? |
| Mar 17, 2015 MForm 4 → | Mar 18, 5:03 pm EDT | Eric K RowinskyDirector | 4,667 | $59.82 | $279,180 | 15,977 | — | plan? |
| Mar 16, 2015 SForm 4 → | Mar 17, 8:10 pm EDT | Kenneth DiPietroEVP Human Resources | 803 | $415.46 | $333,614 | 0 | −100% | plan? |
| Mar 13, 2015 SForm 4 → | Mar 16, 8:39 pm EDT | George A ScangosChief Executive Officer, Director | 537 | $412.69 | $221,613 | 45,176 | −1.17% | plan? |
| Mar 10, 2015 SForm 4 → | Mar 11, 4:17 pm EDT | Stephen A SherwinDirector | 6,000 | $409.67 | $2,458,020 | 4,150 | −59.1% | plan? |
| Mar 10, 2015 SForm 4 → | Mar 11, 4:13 pm EDT | Robert W PangiaDirector | 3,625 | $413.40 | $1,498,578 | 14,873 | −19.6% | plan? |
| Mar 10, 2015 MForm 4 → | Mar 11, 4:13 pm EDT | Robert W PangiaDirector | 3,625 | $47.71 | $172,954 | 15,373 | — | plan? |
| Mar 9, 2015 SForm 4 → | Mar 11, 4:15 pm EDT | Eric K RowinskyDirector | 4,666 | $417.23 | $1,946,795 | 11,310 | −29.2% | plan? |
| Mar 9, 2015 MForm 4 → | Mar 11, 4:15 pm EDT | Eric K RowinskyDirector | 4,666 | $59.82 | $279,120 | 15,976 | — | plan? |
| Mar 6, 2015 GMForm 4 → | Mar 11, 4:17 pm EDT | Stephen A SherwinDirector | 6,275 | $59.82 | $358,920 | 10,150 | — | plan? late |
| Mar 2, 2015 SForm 4 → | Mar 3, 4:44 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 3,174 | $409.49 | $1,299,715 | 9,004 | −26.1% | plan? |
| Mar 2, 2015 SForm 4 → | Mar 3, 4:39 pm EST | George A ScangosChief Executive Officer, Director | 825 | $410.67 | $338,803 | 45,713 | −1.77% | plan? |
| Mar 1, 2015 FForm 4 → | Mar 3, 4:44 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 2,826 | $409.59 | $1,157,501 | 12,178 | — | plan? |
| Feb 19, 2015 SForm 4 → | Feb 20, 4:28 pm EST | George A ScangosChief Executive Officer, Director | 537 | $401.04 | $215,358 | 46,538 | −1.14% | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 4:45 pm EST | George A ScangosChief Executive Officer, Director | 825 | $389.11 | $321,016 | 47,075 | −1.72% | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 4:41 pm EST | Steven H HoltzmanEVP Corporate Development | 2,128 | $389.11 | $828,026 | 4,321 | −33.0% | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 4:37 pm EST | Kenneth DiPietroEVP Human Resources | 1,188 | $389.11 | $462,263 | 803 | −59.7% | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 4:36 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 418 | $389.11 | $162,648 | 15,004 | −2.71% | plan? |
| Feb 12, 2015 MForm 4/A → | Mar 3, 2016, 4:27 pm EST | George A ScangosChief Executive Officer, Director | 9,189 | — | — | 43,466 | — | plan? |
| Feb 12, 2015 FForm 4/A → | Feb 23, 4:24 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 8 | $392.11 | $3,137 | 1,302 | — | plan? |
| Feb 12, 2015 AFMForm 4 → | Feb 17, 9:32 pm EST | George A ScangosChief Executive Officer, Director | 37,873 | $392.11 | $4,754,334 | 47,900 | — | plan? amended |
| Feb 12, 2015 FMForm 4 → | Feb 17, 9:16 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 491 | $392.11 | $7,842 | 1,446 | — | plan? amended |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:54 pm EST | Steven H HoltzmanEVP Corporate Development | 5,346 | $392.11 | $671,292 | 6,449 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:50 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,595 | $392.11 | $154,491 | 1,159 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:47 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 2,362 | $392.11 | $296,827 | 15,422 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:44 pm EST | Paul J ClancyExecutive VP and CFO | 6,325 | $392.11 | $794,415 | 22,257 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:40 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 5,499 | $392.11 | $690,506 | 32,511 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:37 pm EST | Douglas E WilliamsEVP Research & Development | 7,650 | $392.11 | $960,670 | 15,658 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:34 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 5,545 | $392.11 | $696,387 | 27,867 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:30 pm EST | Kenneth DiPietroEVP Human Resources | 5,537 | $392.11 | $695,211 | 1,991 | — | plan? |
| Feb 12, 2015 FMForm 4 → | Feb 17, 8:26 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 5,298 | $392.11 | $665,411 | 8,132 | — | plan? |
| Feb 10, 2015 SForm 4 → | Feb 11, 4:26 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 1,143 | $398.11 | $455,039 | 14,574 | −7.27% | plan? |
| Feb 9, 2015 FMForm 4 → | Feb 11, 4:25 pm EST | George A ScangosChief Executive Officer, Director | 43,914 | $395.76 | $5,465,785 | 34,277 | — | plan? |
| Feb 9, 2015 SForm 4 → | Feb 10, 5:11 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 856 | $398.05 | $340,731 | 14,574 | −5.55% | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:14 pm EST | Douglas E WilliamsEVP Research & Development | 5,102 | $402.00 | $656,868 | 12,908 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:12 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 9,067 | $398.45 | $1,059,889 | 25,874 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:11 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 4,203 | $398.84 | $439,517 | 15,717 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:10 pm EST | Steven H HoltzmanEVP Corporate Development | 3,980 | $402.00 | $512,550 | 4,527 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:08 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 6,203 | $399.47 | $696,283 | 6,228 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:07 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 12,461 | $398.98 | $1,494,979 | 30,534 | — | plan? |
| Feb 8, 2015 FMForm 4 → | Feb 10, 5:06 pm EST | Paul J ClancyExecutive VP and CFO | 11,235 | $398.63 | $1,336,591 | 19,984 | — | plan? |
| Feb 6, 2015 GForm 4 → | Feb 10, 5:04 pm EST | Brian S PosnerDirector | 250 | — | — | 5,450 | — | plan? |
| Feb 2, 2015 SForm 4 → | Feb 3, 6:35 pm EST | Kenneth DiPietroEVP Human Resources | 1,656 | $389.03 | $644,234 | 0 | −100% | plan? |
| Feb 1, 2015 FMForm 4 → | Feb 2, 7:46 pm EST | Kenneth DiPietroEVP Human Resources | 3,270 | $389.16 | $314,052 | 1,656 | — | plan? |
| Feb 1, 2015 FMForm 4 → | Feb 2, 7:43 pm EST | Douglas E WilliamsEVP Research & Development | 7,216 | $389.16 | $801,280 | 11,074 | — | plan? |
| Feb 1, 2015 FMForm 4 → | Feb 2, 7:40 pm EST | Steven H HoltzmanEVP Corporate Development | 7,217 | $389.16 | $801,670 | 3,097 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2016 AForm 4 → | Feb 24, 6:07 pm EST | Adam KoppelEVP, Strategy and Bus. Dev. | 7,270 | — | — | 7,270 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:03 pm EST | George A ScangosChief Executive Officer, Director | 19,683 | — | — | 10,502 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:01 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,692 | — | — | 2,448 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:00 pm EST | Kenneth DiPietroEVP Human Resources | 4,734 | — | — | 2,494 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:59 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 571 | — | — | 258 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:57 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 5,458 | — | — | 10,006 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:56 pm EST | Steven H HoltzmanEVP Corporate Development | 4,588 | — | — | 2,448 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:55 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 4,810 | — | — | 2,674 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:54 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,512 | — | — | 804 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:53 pm EST | Paul J ClancyExecutive VP and CFO | 5,253 | — | — | 2,448 | — | |
| Feb 9, 2016 MForm 4 → | Feb 10, 4:19 pm EST | George A ScangosChief Executive Officer, Director | 11,274 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 10, 4:17 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 1,278 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:58 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 2,498 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:53 pm EST | Paul J ClancyExecutive VP and CFO | 3,194 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:51 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,026 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:48 pm EST | Steven H HoltzmanEVP Corporate Development | 2,709 | — | — | 0 | — | |
| Feb 1, 2016 MForm 4/A → | Feb 9, 5:08 pm EST | Kenneth DiPietroEVP Human Resources | 2,466 | — | — | 1 | — | |
| Feb 1, 2016 MForm 4 → | Feb 2, 4:05 pm EST | Kenneth DiPietroEVP Human Resources | 2,466 | — | — | 1 | — | amended |
| Oct 1, 2015 JMForm 4 → | Oct 5, 4:10 pm EDT | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 4,262 | — | — | 8,528 | — | |
| Jun 2, 2015 JMForm 4 → | Jun 4, 5:49 pm EDT | Adam KoppelSVP, Chief Strategy Officer | 3,612 | — | — | 7,228 | — | |
| May 1, 2015 MForm 4 → | May 5, 4:36 pm EDT | Gregory F CovinoVP, Chief Accounting Officer | 347 | — | — | 348 | — | |
| Apr 2, 2015 MForm 4 → | Apr 3, 4:24 pm EDT | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 975 | — | — | 975 | — | |
| Mar 25, 2015 MForm 4 → | Mar 26, 4:31 pm EDT | John CoxEVP Pharmaceutical Oper & Tech | 5,066 | — | — | 2,892 | — | |
| Mar 20, 2015 MForm 4 → | Mar 23, 4:33 pm EDT | Eric K RowinskyDirector | 11,667 | — | — | 0 | — | |
| Mar 19, 2015 MForm 4 → | Mar 20, 5:03 pm EDT | Eric K RowinskyDirector | 2,333 | — | — | 11,667 | — | |
| Mar 17, 2015 MForm 4 → | Mar 18, 5:03 pm EDT | Eric K RowinskyDirector | 4,667 | — | — | 14,000 | — | |
| Mar 10, 2015 MForm 4 → | Mar 11, 4:17 pm EDT | Stephen A SherwinDirector | 6,000 | — | — | 10,675 | — | |
| Mar 10, 2015 MForm 4 → | Mar 11, 4:13 pm EDT | Robert W PangiaDirector | 3,625 | — | — | 5,450 | — | |
| Mar 9, 2015 MForm 4 → | Mar 11, 4:15 pm EDT | Eric K RowinskyDirector | 4,666 | — | — | 18,667 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:20 pm EST | George A ScangosChief Executive Officer, Director | 26,550 | — | — | 26,550 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:19 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 6,220 | — | — | 6,220 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:18 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 7,260 | — | — | 7,260 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:16 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 3,110 | — | — | 3,110 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:15 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,300 | — | — | 1,300 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:14 pm EST | Paul J ClancyExecutive VP and CFO | 5,190 | — | — | 5,190 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:13 pm EST | Douglas E WilliamsEVP Research & Development | 8,300 | — | — | 8,300 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:11 pm EST | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 4,460 | — | — | 4,460 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:10 pm EST | Steven H HoltzmanEVP Corporate Development | 5,190 | — | — | 5,190 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:08 pm EST | Adam KoppelSVP, Chief Strategy Officer | 2,700 | — | — | 2,700 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:07 pm EST | Kenneth DiPietroEVP Human Resources | 5,700 | — | — | 5,700 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:06 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 600 | — | — | 600 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:02 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 5,700 | — | — | 5,700 | — | |
| Feb 12, 2015 MForm 4/A → | Mar 3, 2016, 4:27 pm EST | George A ScangosChief Executive Officer, Director | 9,189 | — | — | 18,380 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 9:32 pm EST | George A ScangosChief Executive Officer, Director | 19,692 | — | — | 20,996 | — | amended |
| Feb 12, 2015 JMForm 4 → | Feb 17, 9:16 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 571 | — | — | 514 | — | amended |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:54 pm EST | Steven H HoltzmanEVP Corporate Development | 4,588 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:50 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,512 | — | — | 1,602 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:47 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 2,124 | — | — | 2,668 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:44 pm EST | Paul J ClancyExecutive VP and CFO | 5,253 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:40 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,692 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:37 pm EST | Douglas E WilliamsEVP Research & Development | 6,241 | — | — | 5,342 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:34 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 4,810 | — | — | 5,342 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:30 pm EST | Kenneth DiPietroEVP Human Resources | 4,734 | — | — | 4,982 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:26 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 4,468 | — | — | 4,448 | — | |
| Feb 9, 2015 MForm 4 → | Feb 11, 4:25 pm EST | George A ScangosChief Executive Officer, Director | 30,103 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:14 pm EST | Douglas E WilliamsEVP Research & Development | 3,468 | — | — | 3,471 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:12 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 6,407 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:11 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 3,101 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:10 pm EST | Steven H HoltzmanEVP Corporate Development | 2,705 | — | — | 2,709 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:08 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 4,460 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:07 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 8,714 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:06 pm EST | Paul J ClancyExecutive VP and CFO | 7,882 | — | — | 0 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:46 pm EST | Kenneth DiPietroEVP Human Resources | 2,463 | — | — | 2,467 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:43 pm EST | Douglas E WilliamsEVP Research & Development | 5,157 | — | — | 0 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:40 pm EST | Steven H HoltzmanEVP Corporate Development | 5,157 | — | — | 0 | — |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2017 JForm 4 → | Feb 1, 5:21 pm EST | Bioverativ Inc.BIVV | 107,975,968 | — | — | 0 | — | plan? |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.